//Gamaleya Centre launches preclinical trials of new COVID-19 drug on apes

Gamaleya Centre launches preclinical trials of new COVID-19 drug on apes

The Gamaleya Research Center for Epidemiology and Microbiology, which developed the world’s first vaccine against coronavirus Sputnik V, has launched preclinical studies of a new drug for the prevention of COVID-19, Pharmvestnik publication reports, citing data from the public procurement website.
The new vaccine was created using a technology that differs from the one used for the first drug. The new vaccine uses the technology of virus-like particles that do not contain the genetic material of the causative agent, but mimic it instead, thus forcing the body to give an immune response to the virus infiltration.
The preclinical studies of the vaccine are being carried out on animals, and they are to be completed on November 24 — December 20, the publication said. The studies will be conducted on the basis of six institutions.